| Title |
Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review
|
|---|---|
| Published in |
Open Access Journal of Contraception, August 2016
|
| DOI | 10.2147/oajc.s97013 |
| Pubmed ID | |
| Authors |
Iñaki Lete, Oihane Lapuente |
| Abstract |
Premenstrual syndrome and its most severe form, premenstrual dysphoric disorder (PMDD), are two well-defined clinical entities that affect a considerable number of women. Progesterone metabolites and certain neurotransmitters, such as gamma-aminobutyric acid and serotonin, are involved in the etiology of this condition. Until recently, the only treatment for women with PMDD was psychoactive drugs, such as selective serotonin reuptake inhibitors. Several years ago, there has been evidence of the beneficial role of combined hormonal contraceptives in controlling PMDD symptoms. Oral combined hormonal contraceptives that contain drospirenone in a 24+4-day regimen are the only drugs that have been approved by US Food and Drug Administration for the treatment of PMDD, but there is scientific evidence that other agents, with other formulations and regimens, could also be effective for the treatment of this condition. However, it remains unclear whether the beneficial effect of combined hormonal contraceptives is associated with the type of estrogen or progestogen used or the treatment regimen. |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 19% |
| Student > Master | 12 | 16% |
| Student > Doctoral Student | 10 | 13% |
| Researcher | 6 | 8% |
| Lecturer | 5 | 7% |
| Other | 7 | 9% |
| Unknown | 21 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 23% |
| Psychology | 11 | 15% |
| Nursing and Health Professions | 9 | 12% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Neuroscience | 5 | 7% |
| Other | 8 | 11% |
| Unknown | 20 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 May 2021.
All research outputs
#1,045,152
of 25,748,735 outputs
Outputs from Open Access Journal of Contraception
#1
of 1 outputs
Outputs of similar age
#19,920
of 382,496 outputs
Outputs of similar age from Open Access Journal of Contraception
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.5. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 382,496 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them